Steven J. Padula

An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis.

Nancy H. Ruddle, Cheryl M. Bergman, Katherine McGrath et al. · The Journal of Experimental Medicine · 1990 · 693 citations · Full text

Immunotoxicology, Humoral Response, Immunology +20

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

Kim Papp, Andrew Blauvelt, Michael Bukhalo et al. · New England Journal of Medicine · 2017 · 504 citations · Full text

The Nuclear Receptor PPARγ and Immunoregulation: PPARγ Mediates Inhibition of Helper T Cell Responses

Robert B. Clark, David Bishop‐Bailey, Tatiana Estrada-Hernandez et al. · The Journal of Immunology · 2000 · 458 citations · Full text

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Brian G. Feagan, William J. Sandborn, Geert D’Haens et al. · The Lancet · 2017 · 435 citations · Full text

Inflammation, Rheumatology, Placebo-controlled Phase 2 +8

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei et al. · Annals of the Rheumatic Diseases · 2018 · 359 citations · Full text